Description: NGM Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of novel therapeutics for the treatment of cardio-metabolic, liver, oncologic, and ophthalmic diseases. The company's product candidates include NGM282, an engineered variant of the FGF19 human hormone in Phase 2 clinical trials for the treatment of non-alcoholic steatohepatitis (NASH); NGM313, an agonistic antibody that selectively activates fibroblast growth factor receptor 1c-beta-klotho, which is in Phase 1b early proof-of-concept clinical trials for use in the treatment of type 2 diabetes and NASH; and NGM386 and NGM395, which are engineered variants of the GDF15 human hormone for use in the treatment of obesity. Its products under development also comprise NGM120, an antagonistic antibody binding glial cell-derived neurotrophic factor receptor alpha-like that is in Phase 1 clinical trials to inhibit the effects of elevated GDF15 levels on cancer anorexia/cachexia syndrome; NGM217, an antibody in Phase 1 clinical trials to restore pancreatic islet function and increase insulin production in patients with diabetes; and NGM621, an antibody in preclinical studies to decrease levels of a protein implicated in the dry form of age-related macular degeneration. The company has research collaboration, product development, and license agreements with Merck Sharp & Dohme Corp., MedImmune Limited, and JDRF International. NGM Biopharmaceuticals, Inc. was incorporated in 2007 and is headquartered in South San Francisco, California.
Home Page: www.ngmbio.com
NGM Technical Analysis
333 Oyster Point Boulevard
South San Francisco,
CA
94080
United States
Phone:
650 243 5555
Officers
| Name | Title |
|---|---|
| Mr. William J. Rieflin J.D. | Exec. Chairman of Directors |
| Dr. David J. Woodhouse Ph.D. | CEO & Director |
| Ms. Siobhan Nolan Mangini | Pres, Principal Financial, Accounting Officer & CFO of NGM Biopharmaceuticals |
| Dr. Jin-Long Chen Ph.D. | Founder, Chief Scientific Officer & Director |
| Ms. Valerie L. Pierce J.D. | Sr. VP, Gen. Counsel, Sec. & Chief Compliance Officer |
| Dr. Hsiao Dee Lieu | Chief Medical Officer & Sr. VP |
| Brian Schoelkopf | Sr. Director of Corp. Fin. & IR |
| Mr. Brian Muma | VP of People Operations |
| Dr. Alex DePaoli | Chief Translational Officer & Sr. VP |
| Jessica Ferreyra Ph.D. | Chief of Staff, Research |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.4436 |
| Price-to-Sales TTM: | 7.3272 |
| IPO Date: | 2019-04-04 |
| Fiscal Year End: | December |
| Full Time Employees: | 225 |